AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Sponsor: Anshan Tumor Hospital
This PHASE2 trial investigates Breast Neoplasm Female and is currently ongoing. Anshan Tumor Hospital leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
8 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Unknown PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Not Yet Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Anshan Tumor Hospital
- Chaoyang Central Hospital
- Fukuang General Hospital of Liaoning health industry group
- Huludao central hospital
- Liaoning Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.